Volume 9, Number 10—October 2003
Research
Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada
Brian Clarke*, Margot Hiltz*, Heather Musgrave*, and Kevin R. Forward*
Table 2
Effect of serial passage on cefoxitin gradient on promoter and attenuator regions and outer membrane protein profiles of laboratory wild type Escherichia colia,b
| Strain | MIC before serial passage (μg/mL) | MIC after serial passage (μg/mL) | Outer membrane protein profile |
|---|---|---|---|
| LD1 |
<2 |
>32 |
None |
| LD2 |
<2 |
>32 |
Omp C-, Omp F- |
| LD3 |
<2 |
16 |
Omp C-, Omp F- |
| LD4 |
<2 |
>32 |
Omp C-, Omp F- |
| LD5 |
<2 |
>32 |
Omp C-, Omp F- |
| LD6 |
<2 |
8 |
Not done |
| LD7 |
<2 |
4 |
Not done |
| LD8 |
<2 |
16 |
Omp C-, Omp F- |
| LD9 |
<2 |
>32 |
Omp C- , Omp F- |
| LD10 | <2 | >32 | Decreased production of OmpC/F |
aOnly those mutations that arose following serial passage are shown. Some parental strains had mutations initially, which were retained in the mutants.
bNo promoter/attenuator mutations affected β-lactamase production.
Page created: January 10, 2011
Page updated: January 10, 2011
Page reviewed: January 10, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.